Shots:
- DCGI has granted a EUA for tocilizumab in India for the treatment of COVID-19 in hospitalized adults who receives systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or ECMO
- Hetero’s Tocira will be marketed by Hetero Healthcare in India & manufactured by Hetero Biologics
- Tocilizumab (400mg/20ml) is the biosimilar referencing Roche’s Actemra/RoActemra and is expected to be available at the end of Sept’21
Click here to read full press release/ article | Ref: Hetero | Image: Pharma Boardroom
The post Hetero’s Tocira (biosimilar, tocilizumab) Receives the DCGI’s EUA for the Treatment of COVID-19 in Hospitalized Adults first appeared on PharmaShots.
